Cargando…

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ong...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yucai, Nowakowski, Grzegorz S., Wang, Michael L., Ansell, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914042/ https://www.ncbi.nlm.nih.gov/pubmed/29685160 http://dx.doi.org/10.1186/s13045-018-0601-9

Ejemplares similares

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
por: Villasboas, Jose Caetano, et al.
Publicado: (2016)

Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma
por: Hansen, Hinrich P., et al.
Publicado: (2020)

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma
por: Hanauer, Julia D.S., et al.
Publicado: (2018)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
por: Jalali, Shahrzad, et al.
Publicado: (2019)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
por: Mohty, Razan, et al.
Publicado: (2021)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

CD30 induces Reed‐Sternberg cell‐like morphology and chromosomal instability in classic Hodgkin lymphoma cell lines
por: Watanabe, Mariko, et al.
Publicado: (2023)

P035: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
por: Kilian, Annika L., et al.
Publicado: (2022)

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
por: Derenzini, Enrico, et al.
Publicado: (2011)

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
por: Hollander, Peter, et al.
Publicado: (2018)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma
por: Sakatani, Akio, et al.
Publicado: (2020)

CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma
por: Harris, Jonathan A, et al.
Publicado: (2012)

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma
por: Ansell, Stephen M.
Publicado: (2017)

P1091: FEASIBILITY OF ASCT AFTER ANTI-PD-1 THERAPY FOR R/R CLASSICAL HODGKIN LYMPHOMA
por: Mochkin, N., et al.
Publicado: (2022)

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
por: Liu, Weiping, et al.
Publicado: (2023)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

Immune targeting of the microenvironment in classical Hodgkin’s lymphoma: insights for the hematologist
por: Carreau, Nicole A., et al.
Publicado: (2019)

CD20 Over-Expression in Hodgkin-Reed-Sternberg Cells of Classical Hodgkin Lymphoma: the Neglected Quest
por: Benharroch, Daniel, et al.
Publicado: (2015)

Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin’s lymphoma
por: Feng, Xia, et al.
Publicado: (2023)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
por: Allen, Pamela B, et al.
Publicado: (2017)

HLA-G Expression and Role in Advanced-Stage Classical Hodgkin Lymphoma
por: Caocci, G., et al.
Publicado: (2016)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt
por: Mohamed, Osama, et al.
Publicado: (2020)

Anti–PD-1 Therapy–Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma
por: Samoa, Raynald A., et al.
Publicado: (2020)

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019)

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma
por: Wang, Hongyu, et al.
Publicado: (2023)

Mucocutaneous Paraneoplastic Syndrome Secondary to Classical Hodgkin’s Lymphoma
por: Jurkovic, Jenna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0gc322bh64bag6suk6qp0gj3vl